Hemispheric language asymmetry in first episode psychosis and schizotypy: The role of cannabis consumption and cognitive disorganization

Schizophrenia Bulletin

Volumn 41, Issue , 2015, Pages S455-S464

  Herzig, Daniela A ^a,b   Sullivan, Sarah ^c   Lewis, Glyn ^d   Corcoran, Rhiannon ^e   Drake, Richard ^f   Evans, Jonathan ^c   Nutt, David ^g   Mohr, Christine ^b,h  

^a Clienia AG Littenheid   (Switzerland)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

^c UNIVERSITY OF BRISTOL   (United Kingdom)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e UNIVERSITY OF LIVERPOOL   (United Kingdom)

^f UNIVERSITY OF MANCHESTER   (United Kingdom)

^g IMPERIAL COLLEGE LONDON   (United Kingdom)

^h UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

cannabis drugs laterality cognition schizotypy psychosis proneness

Indexed keywords

CANNABIS;

ADOLESCENT; ADULT; AGED; ASSESSMENT OF HUMANS; BRAIN ASYMMETRY; CANNABIS USE; CLINICAL ARTICLE; COGNITION; COGNITIVE DEFECT; COGNITIVE DISORGANIZATION; CONFERENCE PAPER; CONTROLLED STUDY; FEMALE; HUMAN; LEFT HEMISPHERE; MENTAL HEALTH; OXFORD LIVERPOOL INVENTORY OF FEELINGS AND EXPERIENCES; POSITIVE AND NEGATIVE SYNDROME SCALE; POSITIVE SYNDROME; PRIORITY JOURNAL; PSYCHOSIS; RIGHT HANDEDNESS; VISUAL FIELD; DRUG EFFECTS; HEMISPHERIC DOMINANCE; LANGUAGE; MALE; PATHOPHYSIOLOGY; PHYSIOLOGY; PSYCHOTIC DISORDERS; SCHIZOTYPAL PERSONALITY DISORDER; YOUNG ADULT;

ADULT; CANNABIS; FEMALE; FUNCTIONAL LATERALITY; HUMANS; LANGUAGE; MALE; PSYCHOTIC DISORDERS; SCHIZOTYPAL PERSONALITY DISORDER; YOUNG ADULT;

EID: 84926645602     PISSN: 05867614     EISSN: 17451701     Source Type: Journal    
DOI: 10.1093/schbul/sbu179     Document Type: Conference Paper

References (85)

1. Ernst JM, Cacioppo JT. Lonely hearts: Psychological perspectives on loneliness. Appl Prev Psychol. 1999;8:1-22
2. Salize HJ, McCabe R, Bullenkamp J, et al. Cost of treatment of schizophrenia in six European countries. Schizophr Res. 2009;111:70-77
3. Larsen TK, Melle I, Auestad B, et al. Early detection of psychosis: positive effects on 5-year outcome. Psychol Med. 2011;41:1461-1469
4. Hugdahl K, Westerhausen R. The Two Halves of the Brain: Information Processing in the Cerebral Hemispheres. Cambridge, MA/ London, UK: MIT Press; 2010
5. Crow TJ. Schizophrenia as the price that homo sapiens pays for language: a resolution of the central paradox in the origin of the species. Brain Res Rev. 2000;31:118-129
6. Sommer I, Ramsey N, Kahn R, Aleman A, Bouma A. Handedness, language lateralisation and anatomical asymmetry in schizophrenia: meta-analysis. Br J Psychiatry. 2001;178:344-351
7. Broks P. Schizotypy and hemisphere function-II: Performance asymmetry on a verbal divided visual-field task. Pers Indiv Differ. 1984;5:649-656
8. Mohr C, Krummenacher P, Landis T, Sandor PS, Fathi M, Brugger P. Psychometric schizotypy modulates levodopa effects on lateralized lexical decision performance. J Psychiatr Res. 2005;39:241-250
9. Chapman LJ, Chapman JP, Kwapil TR, Eckblad M, Zinser MC. Putatively psychosis-prone subjects 10 years later. J Abnorm Psychol. 1994;103:171-183
10. Mason O, Claridge G, Jackson M. New scales for the assessment of schizotypy. Pers Indiv Differ. 1995;18:7-13
11. Meehl PE. Schizotaxia, schizotypy, schizophrenia. Am Psychol. 1962;17:827-838
12. Liddle PF. The symptoms of chronic schizophrenia. A reexamination of the positive-negative dichotomy. Br J Psychiatry. 1987;151:145-151
13. Raine A. The SPQ: a scale for the assessment of schizotypal personality based on DSM-III-R criteria. Schizophr Bull. 1991;17:555-564
14. Gooding DC, Tallent KA, Matts CW. Clinical status of at-risk individuals 5 years later: further validation of the psychometric high-risk strategy. J Abnorm Psychol. 2005;114:170-175
15. Zammit S, Allebeck P, Andreasson S, Lundberg I, Lewis G. Self reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: historical cohort study. Br Med J. 2002;325:1199-1201
16. van Os J, Bak M, Hanssen M, Bijl RV, De Graaf R, Verdoux H. Cannabis use and psychosis: a longitudinal populationbased study. Am J Epidemiol. 2002;156:319-327
17. DSouza DC, Sewell RA, Ranganathan M. Cannabis and psychosis/schizophrenia: human studies. Eur Arch Psychiatry Clin Neurosci. 2009;259:413-431
18. Regier DA, Farmer ME, Rae DS, et al. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA. 1990;264:2511-2518
19. Moore THM, Zammit S, Lingford-Hughes A, et al. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet. 2007;370:319-328
20. Cohen AS, Buckner JD, Najolia GM, Stewart DW. Cannabis and psychometrically-defined schizotypy: use, problems and treatment considerations. J Psychiatr Res. 2011;45:548-554
21. Barkus E, Murray RM. Substance use in adolescence and psychosis: clarifying the relationship. Annu Rev Clin Psychol. 2010;6:365-389
22. Abdullaev Y, Posner MI, Nunnally R, Dishion TJ. Functional MRI evidence for inefficient attentional control in adolescent chronic cannabis abuse. Behav Brain Res. 2010;215:45-57
23. Mathew RJ, Wilson WH, Turkington TG, et al. Time course of tetrahydrocannabinol-induced changes in regional cerebral blood flow measured with positron emission tomography. Psychiatry Res. 2002;116:173-185
24. Medina KL, Schweinsburg AD, Cohen-Zion M, Nagel BJ, Tapert SF. Effects of alcohol and combined marijuana and alcohol use during adolescence on hippocampal volume and asymmetry. Neurotoxicol Teratol. 2007;29:141-152
25. OLeary DS, Block RI, Koeppel JA, et al. Effects of smoking marijuana on brain perfusion and cognition. Neuropsychopharmacology. 2002;26:802-816
26. OLeary DS, Block RI, Koeppel JA, et al. Effects of smoking marijuana on focal attention and brain blood flow. Hum Psychopharmacol. 2007;22:135-148
27. Grant JE, Chamberlain SR, Schreiber L, Odlaug BL. Neuropsychological deficits associated with cannabis use in young adults. Drug Alcohol Depend. 2012;121:159-162
28. Pope HG , Gruber AJ, Hudson JI, Huestis MA, Yurgelun-Todd D. Neuropsychological performance in long-term cannabis users. Arch Gen Psychiatry. 2001;58:909-915
29. Keri S, Janka Z. Critical evaluation of cognitive dysfunctions as endophenotypes of schizophrenia. Acta Psychiatr Scand. 2004;110:83-91
30. Gooding DC, Matts CW, Rollmann EA. Sustained attention deficits in relation to psychometrically identified schizotypy: evaluating a potential endophenotypic marker. Schizophr Res. 2006;82:27-37
31. Koychev I, McMullen K, Lees J, et al. A validation of cognitive biomarkers for the early identification of cognitive enhancing agents in schizotypy: a three-center doubleblind placebo-controlled study. Eur Neuropsychopharmacol. 2012;22:469-481
32. Skosnik PD, Spatz-Glenn L, Park S. Cannabis use is associated with schizotypy and attentional disinhibition. Schizophr Res. 2001;48:83-92
33. Schafer G, Feilding A, Morgan CJ, Agathangelou M, Freeman TP, Valerie Curran H. Investigating the interaction between schizotypy, divergent thinking and cannabis use. Conscious Cogn. 2012;21:292-298
34. Cappe C, Herzog MH, Herzig DA, Brand A, Mohr C. Cognitive disorganisation in schizotypy is associated with deterioration in visual backward masking. Psychiatry Res. 2012;200:652-659
35. Herzig DA, Tracy J, Munafo M, Mohr C. The influence of tobacco consumption on the relationship between schizotypy and hemispheric asymmetry. J Behav Ther Exp Psychiatry. 2010;41:397-408
36. Herzig DA, Mohr C. Stressing schizotypy: The modulating role of stress-relieving behaviours and intellectual capacity on functional hemispheric asymmetry. Laterality. 2012;18(2):1-27
37. Herzig DA, Brooks R, Mohr C. Inferring about individual drug and schizotypy effects on cognitive functioning in polydrug using mephedrone users before and after clubbing. Hum Psychopharmacol. 2013;28:168-182
38. Kerns JG, Becker TM. Communication disturbances, working memory, and emotion in people with elevated disorganized schizotypy. Schizophr Res. 2008;100:172-180
39. McCreery C, Claridge G. Healthy schizotypy: the case of outof-the-body experiences. Pers Indiv Differ. 2002;32:141-154
40. Schofield K, Claridge G. Paranormal experiences and mental health: Schizotypy as an underlying factor. Pers Indiv Differ. 2007;43:1908-1916
41. Liouta E, Smith AD, Mohr C. Schizotypy and pseudoneglect: a critical update on theories of hemispheric asymmetries. Cogn Neuropsychiatry 2008;13:112-134
42. Suzuki A, Usher M. Individual differences in language lateralisation, schizotypy and the remote-associate task. Pers Indiv Differ. 2009;46:622-626
43. Mass R, Bardong C, Kindl K, Dahme B. Relationship between cannabis use, schizotypal traits, and cognitive function in healthy subjects. Psychopathology. 2001;34:209-214
44. Szoke A, Galliot AM, Richard JR, et al. Association between cannabis use and schizotypal dimensions-a meta-analysis of cross-sectional studies. Psychiatry Res. 2014;219:58-66
45. Schultze-Lutter F, Klosterkotter J, Ruhrmann S. Improving the clinical prediction of psychosis by combining ultra-high risk criteria and cognitive basic symptoms. Schizophr Res. 2014;154:100-106
46. Ventura J, Thames AD, Wood RC, Guzik LH, Hellemann GS. Disorganization and reality distortion in schizophrenia: a meta-analysis of the relationship between positive symptoms and neurocognitive deficits. Schizophr Res. 2010;121:1-14
47. Oldfield RC. The assessment and analysis of handedness: the Edinburgh inventory. Neuropsychologia. 1971;9:97-113
48. Sullivan S, Lewis G, Mohr C, et al. The longitudinal association between social functioning and theory of mind in firstepisode psychosis. Cogn Neuropsychiatry. 2014;19:58-80
49. Herzig DA, Nutt D, Mohr C. Alcohol and relatively pure cannabis use, but not schizotypy, are associated with cognitive attenuations. Front Psychiatry. 2014;5
50. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13:261-276
51. Wallwork RS, Fortgang R, Hashimoto R, Weinberger DR, Dickinson D. Searching for a consensus five-factor model of the Positive and Negative Syndrome Scale for schizophrenia. Schizophr Res. 2012;137:246-250
52. Nelson HE. National Adult Reading Test (NART) Test Manual. Berkshire, UK: Nfer-Nelson; 1982
53. Mason O, Claridge G. The Oxford-Liverpool Inventory of Feelings and Experiences (O-LIFE): further description and extended norms. Schizophr Res. 2006;82:203-211
54. Bourne VJ. The divided visual field paradigm: methodological considerations. Laterality. 2006;11:373-393
55. Coltheart M. The MRC psycholinguistic database. Q J Exp Psychol A. 1981;33:497-505
56. Field AP. Discovering Statistics Using SPSS. London, UK: Sage; 2009
57. Lindman HR. Analysis of Variance in Complex Experimental Designs. San Francisco: Freeman; 1974
58. Crow TJ. Schizophrenia as the price that homo sapiens pays for language: a resolution of the central paradox in the origin of the species. Brain Res Rev. 2000;31:118-129
59. van Dijk D, Koeter MW, Hijman R, Kahn RS, van Den Brink W. Effect of cannabis use on the course of schizophrenia in male patients: a prospective cohort study. Schizophr Res. 2012;137:50-57
60. Quickfall J, Crockford D. Brain neuroimaging in cannabis use: a review. J Neuropsychiatry Clin Neurosci. 2006;18:318-332
61. Rabin RA, Zakzanis KK, George TP. The effects of cannabis use on neurocognition in schizophrenia: a meta-analysis. Schizophr Res. 2011;128:111-116
62. Jockers-Scherubl MC, Wolf T, Radzei N, et al. Cannabis induces different cognitive changes in schizophrenic patients and in healthy controls. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31:1054-1063
63. Coulston CM, Perdices M, Tennant CC. The neuropsychological correlates of cannabis use in schizophrenia: lifetime abuse/dependence, frequency of use, and recency of use. Schizophr Res. 2007;96:169-184
64. Batalla A, Bhattacharyya S, Yucel M, et al. Structural and functional imaging studies in chronic cannabis users: a systematic review of adolescent and adult findings. PLoS One. 2013;8:e55821
65. Harding IH, Solowij N, Harrison BJ, et al. Functional connectivity in brain networks underlying cognitive control in chronic cannabis users. Neuropsychopharmacology. 2012;37:1923-1933
66. Smith MJ, Cobia DJ, Wang L, et al. Cannabis-Related Working Memory Deficits and Associated Subcortical Morphological Differences in Healthy Individuals and Schizophrenia Subjects. Schizophr Bull. 2013
67. Mohr C, Michel CM, Lantz G, Ortigue S, Viaud-Delmon I, Landis T. Brain state-dependent functional hemispheric specialization in men but not in women. Cereb Cortex. 2005;15:1451-1458
68. Boles DB, Barth JM, Merrill EC. Asymmetry and performance: toward a neurodevelopmental theory. Brain Cogn. 2008;66:124-139
69. Ferraro L, Russo M, OConnor J, et al. Cannabis users have higher premorbid IQ than other patients with first onset psychosis. Schizophr Res. 2013;150:129-135
70. Alvarez FJ, Lafuente H, Rey-Santano MC, et al. Neuroprotective effects of the nonpsychoactive cannabinoid cannabidiol in hypoxic-ischemic newborn piglets. Pediatr Res. 2008;64:653-658
71. Sarne Y, Mechoulam R. Cannabinoids: between neuroprotection and neurotoxicity. Curr Drug Targets CNS Neurol Disord. 2005;4:677-684
72. Schubart CD, Sommer IE, Fusar-Poli P, De Witte L, Kahn RS, Boks MP. Cannabidiol as a potential treatment for psychosis. Eur Neuropsychopharmacol. 2014;24:51-64
73. Schubart CD, Sommer IE, van Gastel WA, Goetgebuer RL, Kahn RS, Boks MP. Cannabis with high cannabidiol content is associated with fewer psychotic experiences. Schizophr Res. 2011;130:216-221
74. Morgan CJA, Curran HV. Effects of cannabidiol on schizophrenia-like symptoms in people who use cannabis. Br J Psychiatry. 2008;192:306-307
75. Kowal MA, Hazekamp A, Colzato LS, van Steenbergen H, Hommel B. Modulation of cognitive and emotional processing by cannabidiol: the role of the anterior cingulate cortex. Front. Neurosci. 2013;7:147
76. Schwarcz G, Karajgi B, McCarthy R. Synthetic delta-9-tetrahydrocannabinol (dronabinol) can improve the symptoms of schizophrenia. J Clin Psychopharmacol. 2009;29:255-258
77. Zammit S, Moore THM, Lingford-Hughes A, et al. Effects of cannabis use on outcomes of psychotic disorders: systematic review. Br J Psychiatry. 2008;193:357-363
78. Galderisi S, Mucci A, Mignone ML, Bucci P, Maj M. Hemispheric asymmetry and psychopathological dimensions in drug-free patients with schizophrenia. Int J Psychophysiol. 1999;34:293-301
79. Debbane M, Badoud D, Balanzin D, Eliez S. Broadly defined risk mental states during adolescence: disorganization mediates positive schizotypal expression. Schizophr Res. 2013;147:153-156
80. Szoke A, Galliot AM, Richard JR, et al. Association between cannabis use and schizotypal dimensions-a meta-analysis of cross-sectional studies. Psychiatry Res. 2014;219:58-66
81. Belanger RE, Akre C, Kuntsche E, Gmel G, Suris J-C. Adding tobacco to cannabis-its frequency and likely implications. Nicotine Tob Res. 2011
82. Kristensen K, Cadenhead KS. Cannabis abuse and risk for psychosis in a prodromal sample. Psychiatry Res. 2007;151:151-154
83. Hahn C, Neuhaus AH, Pogun S, et al. Smoking reduces language lateralization: a dichotic listening study with control participants and schizophrenia patients. Brain Cogn. 2011;76:300-309
84. Zubieta J-K, Lombardi U, Minoshima S, et al. Regional cerebral blood flow effects of nicotine in overnight abstinent smokers. Biol Psychiatry. 2001;49:906-913
85. Domino EF, Minoshima S, Guthrie SK, et al. Effects of nicotine on regional cerebral glucose metabolism in awake resting tobacco smokers. Neuroscience. 2000;101:277-282